180 related articles for article (PubMed ID: 12767280)
1. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
Haidar S; Ehmer PB; Barassin S; Batzl-Hartmann C; Hartmann RW
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):555-62. PubMed ID: 12767280
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
Barrie SE; Potter GA; Goddard PM; Haynes BP; Dowsett M; Jarman M
J Steroid Biochem Mol Biol; 1994 Sep; 50(5-6):267-73. PubMed ID: 7918112
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17).
Hartmann RW; Hector M; Wachall BG; Palusczak A; Palzer M; Huch V; Veith M
J Med Chem; 2000 Nov; 43(23):4437-45. PubMed ID: 11087568
[TBL] [Abstract][Full Text] [Related]
4. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Yoden T; Okada M; Fujikura T; Akaza H; Shikama H
Prostate; 1998 Sep; 37(1):10-8. PubMed ID: 9721064
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alpha-hydroxylase/C17,20-lyase.
Duc I; Bonnet P; Duranti V; Cardinali S; Rivière A; De Giovanni A; Shields-Botella J; Barcelo G; Adje N; Carniato D; Lafay J; Pascal JC; Delansorne R
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):537-42. PubMed ID: 12767278
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
Hartmann RW; Hector M; Haidar S; Ehmer PB; Reichert W; Jose J
J Med Chem; 2000 Nov; 43(22):4266-77. PubMed ID: 11063622
[TBL] [Abstract][Full Text] [Related]
7. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
8. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
9. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors.
Jarman M; Barrie SE; Llera JM
J Med Chem; 1998 Dec; 41(27):5375-81. PubMed ID: 9876107
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
[TBL] [Abstract][Full Text] [Related]
12. 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha).
Ling YZ; Li JS; Liu Y; Kato K; Klus GT; Brodie A
J Med Chem; 1997 Sep; 40(20):3297-304. PubMed ID: 9379450
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
14. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.
Nnane IP; Njar VC; Liu Y; Lu Q; Brodie AM
J Steroid Biochem Mol Biol; 1999 Dec; 71(3-4):145-52. PubMed ID: 10659703
[TBL] [Abstract][Full Text] [Related]
15. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
16. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
17. Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)-lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli.
Ehmer PB; Jose J; Hartmann RW
J Steroid Biochem Mol Biol; 2000 Dec; 75(1):57-63. PubMed ID: 11179909
[TBL] [Abstract][Full Text] [Related]
18. Novel steroidal pyrimidyl inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase).
Haidar S; Ehmer PB; Hartmann RW
Arch Pharm (Weinheim); 2001 Dec; 334(12):373-4. PubMed ID: 11852531
[No Abstract] [Full Text] [Related]
19. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.
Wachall BG; Hector M; Zhuang Y; Hartmann RW
Bioorg Med Chem; 1999 Sep; 7(9):1913-24. PubMed ID: 10530940
[TBL] [Abstract][Full Text] [Related]
20. 4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase.
Li J; Li Y; Son C; Banks P; Brodie A
J Steroid Biochem Mol Biol; 1992 May; 42(3-4):313-20. PubMed ID: 1606043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
